Global Biliary Atresia Treatment Market, By Drugs (Bile Acids Analogues, Antibiotics, Corticosteroids, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Biliary Atresia Treatment Market Analysis and Size
The global biliary atresia treatment market is expected to witness significant growth during the forecast period. The factors that boosted the growth of biliary atresia treatment market are increase in biliary atresia patient alongwith vulnerable aging population across the world. Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally causing in interruptions in import and export activities of biliary atresia treatment market. The disease prevalence is very rare.
Data Bridge Market Research analyses a growth rate in the global biliary atresia treatment market in the forecast period 2022-2029. The expected CAGR of global biliary atresia treatment market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 915 million in 2021, and it would grow upto USD 1693.60 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Biliary atresia is also known as extrahepatic ductopenia or sometimes as progressive obliterative cholangiopathy which is defined as a type of rare hepatological disorder affecting mostly new-borns. In patients having biliary atresia, the bile ducts are abnormally very narrow or at times blocked which possibly damage the liver or causes liver cirrhosis. This disease prevalence is rising and important diagnostic procedures and treatments will boost the growth of the market.
Biliary Atresia Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Bile Acids Analogues, Antibiotics, Corticosteroids, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Merck KGaA (Germany), Beckman Coulter Inc. (U.S.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals LLC. (U.K.)
|
|
Market Opportunities
|
|
Global Biliary Atresia Treatment Market Dynamics
Drivers
- Availability of Advanced Treatment Procedures
With each passing decade, varied treatment methods are being available that would help the patients' faster recovery. Development of diverse advanced devices are providing high output, carrying out several tests in a very short duration of time, and reducing weight time significantly. Thus, it acts as a major driver in the market growth.
- Increase in the number of research and development activities
the market growth is boosted by an increase in the number of R&D activities. This will provide beneficial opportunities for the global biliary atresia treatment market. For encouraging researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.
Opportunities
- Strategic Initiatives and Collaborations
Organizations' multiple efforts to design and carry out studies on rare diseases are also expected to help in the growth of the global biliary atresia treatment market during the forecast period. For instance, an organization named as ‘The Childhood Liver Disease Research Network’ (children) is a collaborative team of doctors, medical facilities, nurses, research coordinators, and patient support organizations. This huge organization aims to improve the lives of young people and families suffering from rare liver diseases. The Children Network was launched in October 2019, in order to support the invention of the latest diagnostic, etiologic, treatment options for children with liver disease, and people who undergo liver transplantation. All these factors are also contributing in the growth of the market.
- Increasing Demand for Retail Pharmacies
The rise in the number of drugs used for biliary atresia disease delivered through retail pharmacies and an increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Complications of Biliary Atresia Drugs
There are common complications of biliary atresia, such as liver failure, failure to thrive link and malnutrition, and cirrhosis and related complications. If the patient does not get proper treatment, infants with biliary atresia can develop cirrhosis within six months and liver failure within a year. At the age of 2 years, untreated patients would need to undergo liver transplant to survive. Cirrhosis can lead to complications such as portal hypertension. Portal hypertension means high blood pressure in the portal vein, which is a blood vessel that carries blood from the intestines to the liver. Thus, complications of the drugs associated with biliary atresia.
- Unavailability of Appropriate Treatments
To treat conditions which are rare, many a times, all treatments are not available, especially in the under-developed countries. The severe patients needs to be treated with the advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.
This global biliary atresia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global biliary atresia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Biliary Atresia Treatment Market
COVID-19 has left a major global public health crisis that made an impact practically every business and a heavy impact on the global biliary atresia treatment market. The COVID-19 pandemic has really had a great impact on research and clinical trials of biliary atresia. They have been extremely impacted due to the immense lack of new sample collections. Furthermore, as per the article published by American Association for the Study of Liver Diseases, considerable decline in donations with unparalleled financial challenges and the cancellation of all fundraising events, will definitely impact pediatric liver research funding. But, on a positive note, the COVID-19 pandemic has supported the pediatric hepatology community. For instance, there is this organization called The Society of Pediatric Liver Transplantation–The Transplantation Society and North American Society for Pediatric Gastroenterology, Hepatology & Nutrition has launched a joint national registry for COVID-19 in kids with post–liver transplantation and chronic liver disease.
During the pandemic, many hospitals have decided to cancel or postpone other procedures. Post pandemic, the situation improved a bit and doctors and physicians could focus on the other syndromes, including these rare syndromes. Travel restrictions has uplifted and treatments are expanding at a high pace. Telemedicine in terms of genetic counselling are also on the rise and is really helpful, especially for treating these kind of diseases.
Global Biliary Atresia Treatment Market Scope
The global biliary atresia treatment market is segmented on the basis of drugs, route of administration, distribution channel, end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Bile Acids Analogues
- Antibiotics
- Corticosteroids
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Biliary Atresia Treatment Market Regional Analysis/Insights
The global biliary atresia treatment market is analysed and market size insights and trends are provided by drugs, route of administration, distribution channel, end users as referenced above.
The major countries covered in the global biliary atresia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market due to the increase in awareness about the biliary atresia treatment as well as advanced healthcare facilities.
Asia-Pacific is considered to have the most lucrative period due to the increase government initiatives and high prevalence rate of biliary atresia.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Biliary Atresia Treatment Market Share Analysis
The global biliary atresia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global biliary atresia treatment market.
Key players operating in the global biliary atresia treatment market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Bristol-Myers Squibb Company (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Beckman Coulter Inc. (U.S.)
- Glenmark Pharmaceuticals Inc (India)
- Amneal Pharmaceuticals LLC. (U.K.)
SKU-